Clinical trials: Stage IV Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing…
- Trial name
- REASSURE (NCT02141438)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Argentina and 18 more
- Volunteers
- 1,472 people
- Sponsor
- Bayer
Prostate Cancer
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Primary Objective: To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.
- Trial name
- PROSPECTA (NCT01649635)
- Testing
- CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin
- Where
- 6 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Sanofi
Hormone Refractory Prostate Cancer
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer.
- Trial name
- NCT00493766
- Testing
- LBH589
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061867
- Testing
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- Imunon
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer Metastatic
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Primary Objective: To evaluate the safety of cabazitaxel (Jevtana) in patients with metastatic hormone refractory prostate cancer Secondary Objectives: 1.
- Trial name
- NCT02074137
- Testing
- CABAZITAXEL XRP6258, Prednisone, Prednisolone
- Where
- 3 sites in India
- Volunteers
- 10 people
- Sponsor
- Sanofi
Hormone Refractory Prostate Cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of…
- Trial name
- NCT00571675
- Testing
- AT-101, prednisone and docetaxel
- Where
- 35 sites in United States, Russia
- Volunteers
- 220 people
- Sponsor
- Ascenta Therapeutics
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Prostate Cancer
Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic…
- Trial name
- NCT00004045
- Testing
- exatecan mesylate
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Metastatic Castration-Resistant Prostate Cancer
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide.
- Trial name
- NCT06318273
- Testing
- ABBV-969
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 152 people
- Sponsor
- AbbVie
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer
3-AP in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate…
- Trial name
- NCT00054015
- Testing
- triapine
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals